|
Volumn 47, Issue 3, 2001, Pages 206-210
|
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule
a a a a a |
Author keywords
High dose anthracyclines; High dose ifosfamide; Sequential chemotherapy; Soft tissue sarcomas
|
Indexed keywords
EPIRUBICIN;
IFOSFAMIDE;
MESNA;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
GRANULOCYTE COLONY STIMULATING FACTOR;
ADULT;
AGED;
ARTICLE;
BLOOD TOXICITY;
BONE MARROW SUPPRESSION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTINUOUS INFUSION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
FEVER;
HEMATURIA;
HOSPITALIZATION;
HUMAN;
LEIOMYOSARCOMA;
MALE;
METASTASIS;
NAUSEA;
NEPHROTOXICITY;
NEUROTOXICITY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOFT TISSUE SARCOMA;
STOMATITIS;
TREATMENT OUTCOME;
VOMITING;
ADOLESCENT;
ALOPECIA;
CHEMICALLY INDUCED DISORDER;
HEMATOLOGIC DISEASE;
MIDDLE AGED;
SARCOMA;
SOFT TISSUE TUMOR;
ADOLESCENT;
ADULT;
AGED;
ALOPECIA;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
EPIRUBICIN;
FEMALE;
GRANULOCYTE COLONY-STIMULATING FACTOR;
HEMATOLOGIC DISEASES;
HUMANS;
IFOSFAMIDE;
MALE;
MIDDLE AGED;
NAUSEA;
SARCOMA;
SOFT TISSUE NEOPLASMS;
VOMITING;
|
EID: 0034743354
PISSN: 03445704
EISSN: None
Source Type: Journal
DOI: 10.1007/s002800000219 Document Type: Article |
Times cited : (13)
|
References (22)
|